CalciMedica, Inc. (CALC)
| Market Cap | 4.32M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.74M |
| Shares Out | 823.07K |
| EPS (ttm) | -39.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,145 |
| Open | n/a |
| Previous Close | 5.25 |
| Day's Range | n/a |
| 52-Week Range | 1.00 - 5.28 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 14.00 (+166.67%) |
| Earnings Date | Jun 20, 2023 |
About CALC
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for CALC stock is "Buy" and the 12-month stock price forecast is $14.0.
News
CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)
Results support the initiation of clinical studies to assess Orai1 inhibition in patients with recurrent acute pancreatitis (RAP) and early CP
Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimat...
CalciMedica Expands Executive Team with New Appointments
Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cun...
CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
LA JOLLA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening infla...
CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement
- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected...